We have used a combination of highly specific protein phosphatase inhibitors and purified mammalian protein phosphatases to show that at least two separate Ser/Thr protein phosphatase activities are required for pre-mRNA splicing, but not for spliceosome assembly. Okadaic acid, tautomycin, and microcystin-LR, which are potent and specific inhibitors of PP1 and PP2A, two of the four major types of Ser/Thr-specific phosphatase catalytic subunits, block both catalytic steps of the premRNA splicing mechanism in HeLa nuclear extracts. Inhibition of PP2A inhibits the second step of splicing predominantly while inhibition of both PP1 and PP2A blocks both steps, indicating a differential contribution of PP1 and PP2A activities to the two separate catalytic steps of splicing. Splicing activity is restored to toxininhibited extracts by the addition of highly purified mammalian PPI or PP2A. Protein phosphatase activity was not required for efficient assembly of splicing complexes containing each of the Ul, U2, U4/U6 and U5 snRNPs. The data indicate that reversible protein phosphorylation may play an important role in regulating the pre-mRNA splicing mechanism.
INTRODUCTION
Reversible phosphorylation of proteins is one of the major mechanisms used to regulate cellular processes, including metabolism, initiation of mitosis and progression through the cell cycle, macromolecular synthesis and breakdown, transcription activation and translation. Protein phosphorylation can act either to stimulate or to inhibit cellular processes, since some substrates are activated by addition of phosphate while others are inhibited (1) . Proteins can be phosphorylated on either serine, threonine or tyrosine residues. However, in mammalian cells over 99% of protein phosphorylation takes place on serine and threonine residues, and protein phosphatases (PP) which dephosphorylate these residues are classified as forms of PP1, PP2A, PP2B or PP2C, according to which catalytic subunit is present in the native enzyme (2, 3) . In most cases, the native forms of Ser/Thr-specific protein phosphatases are comprised of one of the catalytic subunits together with additional proteins that modulate their activity and/or substrate specificity and intracellular localisation (2, 3) . All known Ser/Thr-specific phosphatases are sensitive to inhibition by fluoride, pyrophosphate and EDTA (4) . In addition, protein phosphatases containing the PPl or PP2A catalytic subunit can be selectively inhibited by specific toxins such as the polyketal fatty acids okadaic acid and tautomycin and the cyclic heptapeptide microcystin-LR (5, 6, 7) . The great specificity of these toxins has recently led to their widespread use for identifying biological processes that are regulated by forms of PP1 or PP2A enzymes (8, 9) .
In this study we have investigated whether the splicing of mammalian pre-mRNA substrates is also subject to regulation by reversible protein phosphorylation. The splicing of specific pre-mRNAs can be studied in vitro using extracts prepared from HeLa cells (10, 11, 12) . Previous analyses have established that splicing takes place by a two-step mechanism (13, 14) which likely involves two sequential transesterification reactions (15) . The first step involves cleavage of the pre-mRNA at the 5' intron-exon junction, generating reaction intermediates corresponding to the free 5' exon and a 'lariat' intron which is still joined to the 3' exon. The 'lariat' structure results from the formation of a 2'-5' phosphodiester bond linking the 5' end of the intron to a 2'-OH group of an adenosine residue at an intron sequence close to the 3' splice site. The second step results in ligation of the exon sequences to yield mRNA and release of the intron, still in the 'lariat' configuration. Both these catalytic reactions take place within a dedicated complex, termed a spliceosome, and are preceded by a series of assembly steps. The subunits of the splicing apparatus, specifically the U1, U2, U4/U6 and U5 snRNPs, together with other non-snRNP protein splicing factors, associate with the pre-mRNA in an ordered pathway to form a functional spliceosome (16, 17) . The 
HeLa cell nuclear extracts
HeLa cell nuclear extracts were prepared as described previously (20, 21) with the following modification; intact HeLa cells (5 x 109) were harvested by centrifugation and washed once with ice cold PBS. Cells were then pelleted again by centrifugation at 2,000 rpm in an SS34 rotor for 10 minutes at 4°C and resuspended in 5 x the packed cell volume (pcv) of buffer A (10 mM Hepes pH 7.9, 1.5 mM MgC12, 10 mM KCl and 0.5 mM DTI). Cells were incubated on ice for 10 minutes, centrifuged as before and resuspended in 2 x pcv of buffer S (20 mM Hepes pH 7.9, 10% Glycerol, 1.5 mM MgC2, 420 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF and 0.5 mM DTh. Cells were lysed in buffer S by 12 strokes with a Dounce homogenizer using an A-tpe pestle. Additional steps were as described by Barabino et al. (21) .
Splicing assays Splicing assays were done using uniformly labeled, capped premRNAs incubated with nuclear extracts using the in vitro splicing conditions described by Lamond et al. (22) . Adeno pre-mRNA was transcribed from Sau3A-digested plasmid pBSAdl (23) .
Splicing products were separated on 10% polyacrylamide/8 M urea denaturing gels, run in 1 xTBE. Splicing and snRNP complexes were separated on non-denaturing agarosepolyacrylamide composite gels, as described by Lamond et (25) .
Protein phosphatase assays PP1 and PP2A were assayed by the dephosphorylation of 10 /AM glycogen phosphorylase (18, 26) . One Unit of activity is that amount which catalyses the dephosphorylation of 1 jAmole of glycogen phosphorylase in one minute. When inhibitor-2 was included in the assay, diluted nuclear extacts and inhibitors were preincubated for 15 min at 30°C, prior to initiating the reaction by addition of substrate, in order to ensure complete inhibition of PP1.
RESULTS
Inhibition of protein phosphatases blocks splicing The Ser/Thr-specific protein phosphatase inhibitors okadaic acid, tautomycin and microcystin-LR were used to investigate whether protein phosphorylation is involved in the regulation of premRNA splicing in HeLa nuclear extracts (Figure 1 ). In comparison with the control splicing reaction ( Figure 1A In the previous experiments, okadaic acid primarily inhibited the second step of splicing while tautomycin and microcystin-LR blocked both the first and second steps ( Figure IA) . Okadaic acid is known to be a less potent inhibitor of PPl than either tautomycin or microcystin-LR, while all three toxins strongly inhibit PP2A (6, 7, 27) . Given these properties, a major role for a form of PPl at the first catalytic step of splicing would explain why step one was inhibited by tautomycin and microcystin-LR but only weakly by okadaic acid. Since okadaic acid potently inhibited the second step of splicing at the same concentration where the first step was relatively unaffected, the data further indicate a major role for a form of PP2A at step two.
The above model makes two predictions; (a) that okadaic acid should strongly block also the first step of splicing when tested at higher concentrations and (b) that a selective inhibition of the second step of splicing should not occur at lower concentrations of tautomycin or microcystin-LR, since tautomycin inhibits PPl more strongly than PP2A (6) and microcystin-LR inhibits PP1 and PP2A at similar concentrations (7) . To test these predictions the inhibitory effects of all three toxins were assayed over the range of (final) concentrations 2.5 1&M to 10 nM (Figure 3) . At higher concentrations okadaic acid indeed blocked both steps of splicing ( Figure 3A, lanes 3 and 4) . At progressively lower concentrations of okadaic acid increasing levels of splicing intermediates were detected ( Figure 3A, lanes 5-9) , while at the lowest concentration spliced products were also formed ( Figure 3A, lane 10) . The absolute concentration of okadaic acid required to inhibit both steps of splicing varied slightly between different extract preparations and was also influenced by preincubation of the toxin with the nuclear extract. However, for all nuclear extracts tested, okadaic acid showed a concentration dependent, differential inhibitory effect on the first and second steps of splicing. Additional experiments also showed that okadaic acid inhibited splicing even when the incubation time of the splicing assay was extended up to three hours (data not shown). This indicates that okadaic acid causes a major block in splicing, rather than a more modest change in the reaction kinetics. At the higher concentrations tsted, tautomycin and microcystin each blocked both steps of splicing ( Figure 3B and C, lanes 3 and 4). Consistent with their known inhibitory properties, microcystin-LR blocked splicing at lower concentrations than tautomycin (cf. Figure 3B , lanes 5-7 and Figure 3C , lanes 5-7). In contrast with okadaic acid, however, neither drug caused an accumulation of splicing intermediates at lower concentrations but instead allowed both steps of splicing ( Figure 3B and C (Figure 4 ).
Extrats were assayed for splicing activity either in the absence of inhibitors (Figure 4 , A and B, lanes 1) or in the presence of microcystin-LR ( Figure 4A, lanes 2-4) or okadaic acid ( Figure  4B, lanes 2-4) . As observed previously, both microcystin-LR and okadaic acid potently inhbited splicing (Figure 4 , A and B, lanes 2). Addition of highly purified PPl or PP2A to the microcystin-LR or okadaic acid inhibited extracts restored formation of splicing intennediates and products in each case ( Figure 4, A and B, lanes 3 and 4) . In additional experiments, the efficiency of splicing restration was observed to be dependent with the concentrations of inhibitors used in different extracts (data not shown). As shown in Figure 4 , both PP1 and PP2A can restore splicing activity in inhibited extracts to a level comparable with that seen in the uninhibited control extract (Figure 4 , A and B, cf. lanes 1 with lanes 3 and 4) .
Analysis of phosphatase levels in HeLa nuclear splicing extracts From the present study it is inferred that Ser/Thr-specific protein phosphatases, in particular PP1 and PP2A, are required for premRNA splicing. To establish that endogenous protein phosphatase activities of this type are indeed present in the HeLa nuclear extracts used for in vitro splicing experiments, levels of phosphatase activity were measured in such extracts (Table 1) . For these assays dephosphorylation of a standard substrate, phosphorylase a, was measured in the presence and absence of phosphatase inhibitors (for details of assay see Materials and Methods). The results show that both PP1 and PP2A activities are present in HeLa nuclear splicing extracts. Consistent with previous studies of protein phosphatase activity in rat nuclear extracts (28) , the contribution of PPI to the phosphorylase phosphatase assay was greater than that of PP2A in the nuclear splicing extracts. As a further control, measurements were made of phosphatase levels in microcystin-LR-treated HeLa nuclear extracts under conditions where splicing was blocked. This confirmed tat both PP1 and PP2A activities were fully inhibited. We note that the absolute levels of protein phosphatase activity detected in the HeLa nuclear extracts is consistent with our empirical observations of the concentrations of phosphatase inhibitors required to block splicing activity.
In summar, we show that both PP1 and PP2A activities are present in HeLa nuclear extracts, consistent with forms of these enzymes being the phosphatases required for splicing activity. However, it should be noted hat xse assays are performed using a staniard substrate, and that the native forms of the phosphatases connected with splicing may have enhanced activity towards splicing factors and/or suppressed activity towards the standard substrate, as has been found for certain cytosolic forms of PP1 and PP2A (3, 29) . Therefore, the data may not accurately reflect the relative levels of the specific PP1 and PP2A enzymes required for splicing.
DISCUSSION
In this study we have presented evidence that reversible protein phosphorylation may play an important role in controlling premRNA splicing. The highly specific phosphatase inhibitors tautomycin, microcystin-LR and okadaic acid were used to show that Ser/Thr-specific protein phosphatases are required for premRNA splicing in vitro. The crude HeLa nuclear extracts used for in vitro splicing assays clearly contain one or more protein kinases which can utilise the magnesium and ATP present in the splicing reaction to inhibit both steps of pre-mRNA splicing. However, the extracts must also contain sufficiently high levels of endogenous protein phosphatases to compete with the kinase(s) and promote partial or complete dephosphorylation of proteins whose phosphorylation blocks splicing. When phosphatase inhibitors are added to the extract the balance between phosphorylation and dephosphorylation activities is changed and specific proteins therefore become phosphorylated to a degree which inhibits splicing. Interestingly, the phosphatase inhibitors uncouple spliceosome assembly from catalysis; i.e. tautomycin, microcystin-LR and okadaic acid each block both of the catalytic steps of splicing but do not prevent the stable assembly of splicing complexes containing each of the Ul, U2, U4/U6 and U5 snRNPs. Splicing activity could be restored to inhibited extracts by addition of exogenous, highly purified, malian Ser/Thrspecific protein phosphatases, confirming that protein dephosphorylation is essential for splicing in vitro. The data point to distinct protein phosphatases playing a major role during the first and second steps of splicing, indicating that at least two separate dephosphorylation events are required. Previous detailed studies have established that tautomycin, microcystin-LR and okadaic acid are all highly specific inhibitors of the PP1 and PP2A type protein phosphatases (5-9). We therefore infer that it is forms of PPl and PP2A which are required for splicing, although we cannot formally exclude the involvement of a novel, as yet undetected, phosphatase activity which is also sensitive to the same inhibitors. Consistent with a role for PPl and PP2A in splicing, we show here that both activities are present in HeLa nuclear extracts and both are fully inhibited under conditions where splicing is blocked ( Table 1) . The data support a model in which a form of PPl plays a major role for the first step of splicing and a form of PP2A plays a major role for the second step. This is based on the known properties of okadaic acid, which inhibits PPl much less efficiently than PP2A (27) , and our observation that okadaic acid preferentially blocks the second step of splicing unless used at high concentrations. The inhibitory effects of tautomycin and microcystin-LR also support this model since the former is more efficient at inhibiting PPI than PP2A and the latter inhibits both PPl and PP2A with similar efficiency (6, 7) . When used to block splicing, tautomycin and microcystin-LR always inhibit both steps simultaneously. Although the purified catalytic subunits of either PPl or PP2A alone were able to restore both steps of splicing to inhibitor-blocked extracts (Figure 4 ), this does not contradict the above model. Although PP1 appears to be the major phosphatase required for the first step of splicing and PP2A the major phosphatase required for the second step, a lesser contribution of PP2A at step one and PPl at step two is not excluded. In this event it would not be surprising that high concentrations of either PPI or PP2A could rescue both steps of splicing. Furthermore, it is also important to note that the catalytic subunits of phosphatases, in the absence of the additional regulatory subunits present in the native forms of enzymes, frequently show less restricted substrate specificities. This highlights the importance of purifying the native forms of protein phosphatases participating in splicing for future studies.
The present demonstration that Ser/Thr-specific protein dephosphorylation is required for both catalytic steps of splicing is consistent with the results presented in several recent studies (30, 31) . Tazi et al. (30) reported that adenosine phosphorothioates (ATPcvS and ATP-yS) differentially inhibit the two catalytic steps of mammalian pre-mRNA splicing. The authors proposed that some splicing factors could be mammalia equivalents of the yeast RNA helicase-like proteins, while others might undergo phosphorylation-dephosphorylation cycles during spliceosome assembly and splicing. These authors also reported that okadaic acid specifically inhibited the second step of splicing.
Here it is shown that okadaic acid, at high concentrations, inhibits both steps of splicing, rather than just the second step. However, a simple explanation for this difference is that Tazi et al. used okadaic acid at a concentration below that required to block the first step of splicing. Turcq et al. (31) , cloned a gene required for RNA processing and splicing of Neurospora mitochondrial RNAs. The amino acid sequence deduced for this gene product shows similarity to yeast proteins that are imporant for cell-cycle progression and which are putative protein phosphatases or regulos ofprotein phosphatase activity. This evidence, although indirect, suggests that a role for protein phosphatases in the splicing mechanism may turn out to be an evolutionarily conserved feature. This would not be surprising as both the splicing machinery and protein phosphatases show an extremely high degree of evolutionary conservation.
This study shows that one or more protein factors, whose activity is reqWred for completion of the first and second catalytic steps of splicing, are subject to regulaton by the reversible phosphorylation of serine or threonine residues.
While the data indicate that distinct amino-acid targets must be dephosphorylated to allow the first and second catalytic steps of splicing, they do not distinguish whether xhse s rate targets are located witiin the same or in different preins. A major goal for future studies will now be to identify the phosphatase substrates which are required for the splicing mechanism. Such proteins could either be intrinsic components of snRNPs or splicing complexes or else could be extrinsic components which act to modulate the activity of splicing factors. The only major snRNP protein which is known to be phosphorylated in vivo is the Ul snRNP-specific 70 kD protein, which contains phosphoserine residues (32, 33) . In this regard it is interesting that Tazi et al. have recently observed that thiophosphorylation of the U1 70 kD protein blocks the first step of splicing (personal communication).
TIhe demonstration that SerfMr-specific protein phosphatase activity is required for pre-mRNA splicing in vitro raises interesting questions about the physiological role of reversible protein phosphorylation in vio. It may be significant that protein phosphatase activity can uncouple spliceosome assembly from the catalytic steps of splicing as well as the two catalytic steps from each oter. This could terefore allow spliceosome assembly and one or both steps of splicing to take place in different subnuclear locations. Alternatively, phosphorylation control could be used to modulate splicing activity in vivo in response to physiological stimuli, providing a sensitive mechanism for regulating production of spliced mRNA products. Yet another possibility is at the observed effects of phosphorylation are part of the cell-cycle control mechanism which acts to inhibit premRNA splicing during mitosis. To distinguish between hese and other possibilities it will now be important to identify and purify the different phosphatases and related kinases which act to regulate the pre-mRNA splicing machinery.
